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Abbreviations  
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Abstract 
Degree project, Programme in Medicine. A comparison of Catheter-Related Infection in 
oncology patients with Peripherally Inserted Central Catheter versus Totally Implantable 
Central Access Device. Lisa Bjerling, 2017, Department of Infectious Diseases and Infection 
Control, Södra Älvsborg Hospital, Borås, Sweden. University of Gothenburg, Gothenburg, 
Sweden. Supervisor: Maria Werner, MD, PhD. 
 
Introduction: Catheter-Related Infection (CRI) is an important factor for morbidity in patients 
with a Central Venous Access Device (CVAD). The CRI-incidence differ between CVADs. In 
oncological care, CVADs used are for example Totally Implantable Venous Access Device 
(TIVAD) and Peripherally Inserted Central Catheter (PICC).  
Aim: To find whether PICC or TIVAD gives the lowest incidence of CRI in patients with solid 
tumors. 
Method: Records from 556 patients with CVADs (328 PICC and 228 TIVAD) inserted 
between 2015-2016 at Södra Älvsborg Hospital (SÄS) in Sweden were reviewed. The 
comparison of the CRI-incidence was made in two groups: Confirmed CRI and Total CRI 
(Uncertain CRI-episodes included). Data was analyzed with Kaplan-Meier survival function 
and Cox regression. 
Result: 320 patients with 356 CVAD episodes (165 TIVAD and 191 PICC) were analyzed. 200 
patients were excluded (mainly because of that the CVAD was not inserted at SÄS or age <18 
years). In the Total TIVAD CRI-group, 46 CRIs was found (1.04 CRI/1000 catheter-days) and 
26 CRIs was found (1.77 CRI/1000 catheter-days) in the Total PICC CRI-group. In the 
Confirmed TIVAD CRI-group, 24 CRIs was found (0.5 CRI/1000 catheter-days) and 2 CRIs 
(0.13 CRI/1000 catheter-days) in the PICC group. A significantly lower risk of CRI in patients 
with PICC was found in the Confirmed CRI-group (Hazard Ratio=0.093, 95% Confidence 
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Interval=0.01-0.869, p=0.037) but not in the Total CRI-group (Hazard Ratio=1.029, 95% 
Confidence Interval=0.438-2.157, p=0.945). 
Conclusion: In patients with solid tumors there was no significant difference in CRI-incidence 
between PICC and TIVAD. Patients with PICC had a significantly lower CRI-incidence in the 
Confirmed CRI-group, indicating that PICC might be a safer alternative. The CRI-incidence in 
both groups were equivalent with earlier studies. Further prospective studies are needed.  
Keywords: Catheter-Related Infections, Central Venous Catheters, Peripherally Inserted 
Central Catheter, Totally Implantable Venous Access Device.  
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Introduction 
Catheter-Related Infection (CRI) is an important factor for morbidity in patients with a Central 
Venous Access Device (CVAD) and might even be life-threatening if the patient become septic. 
CVADs are afflicted with different CRI-incidence, which is important to know in oncological 
practice, since (1) the patients need a safe long term supply of chemotherapy, large volumes of 
fluids and circulatory surveillance, which a CVAD presents (1).  
Central Venous Access Device (CVAD) 
All CVADs have the catheter tip placed in the vena cava superior, within proximity of the heart 
(2). Common intravenous accesses are listed in Table 1. 
Table 1. Short facts about central catheters used for venous access. Modified from O'Grady (3). 
Catheter type Entry site Usage CRI-risk 
Nontunneled Central Venous 
Catheter (CVC) 
Inserted into subclavian or internal 
jugular vein 
Short term^ High 
Tunneled Central Venous Catheter 
(tCVC) 
Inserted ca 10 cm subcutaneously 
before entering the central vein (1) 
Long term*(2) Low 
Peripherally Inserted Central Venous 
Catheter (PICC) 
Inserted via a peripheral vein 
Intermediate-
Long term*(4) 
Low 
Totally Implantable Central Venous 
Access Device (TIVAD) 
A subcutaneous injection chamber 
with a catheter inserted in the 
subclavian or the internal jugular vein 
Long term*(2) Low 
^Short term: Under 4 weeks.  *Long term: More than 4 weeks.  
CRI=Catheter-Related Infection 
 
In oncological treatment, the most used CVADs are Totally Implantable Venous Access Device 
(TIVAD), Tunneled Central Venous Catheter (tCVC) and Peripherally Inserted Central 
Catheter (PICC), but data is not sufficient to recommend one specific type (5). Lately, PICC 
has become more frequently used, since it has fewer complications, costs less than other 
CVADs and the insertion is easier (1, 6). Oncology patients get infections easier since they have 
poor immune defense (7), partly because of chemotherapy and partly because of the disease. 
For this study to be as uniform as possible, the hematologic malignancies were excluded, since 
these patients often get intensive treatment of chemotherapy, which possibly could make them 
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more prone to get CRI. Hence, the focus 
of the study is on comparing CRI-
incidence in PICC and TIVAD in 
patients with solid tumors. 
PICC 
The PICC can be used for intermediate 
to long time (more than 4 weeks) (4). 
The insertion of a PICC is most often 
done under sterile procedures by a nurse 
(1) with ultrasound guidance (4). The 
catheter is 20 cm or longer, depending on patient length (3). 
TIVAD 
A TIVAD is for long-term (more than 4 
weeks) usage (1, 8). The TIVAD has different 
terms in studies such as: port, port a cath 
(originally a name of a product, now used as a 
synonym for TIVAD), port-chamber catheter, 
Totally Implantable Venous Access Port 
System (TIVAPS) and Implantable Venous 
Access Device (IVAD). 
The TIVAD consists of a chamber with a 
silicone membrane and an attached catheter (1). The chamber is implanted subcutaneously 
under sterile procedures (2). To access the venous blood, a port needle is injected into the 
implanted chamber (1). The needle needs to be changed at least every 5th day for inpatients and 
every 7th for outpatients (8). 
Figure 1. Peripherally Inserted Central Catheter 
inserted in a vein.  
Picture from (35). 
Figure 2. Totally Implantable Venous Access 
Device inserted under the skin and in a vein. 
Port=Totally Implantable Venous Access Device 
Picture from (36). 
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Complications 
Patients with CVAD risk various complications, for example thrombosis, pneumothorax and 
CRI (1, 2), the latter is a common cause for premature catheter removal (9-12). Studies of PICC 
(11, 13, 14) show different complications (% of all episodes): Occlusion (2.4-44.3%), 
thrombosis (3.3-11.7%), CRI (3.2-6.9%) and migration (3.8-13.1%). One study showed that the 
most common complication in TIVAD is CRI (2.3%) and port expulsion (1.7%) (15). The 
results above are presented in percentage and not in CRIs per 1000 catheter-days (See definition 
below under the paragraph Catheter-Related Infection - CRI-incidence). 
Catheter-Related Infection (CRI) 
Definition 
The definition of CRI differs among studies, which make them hard to compare. The most 
common definitions are Catheter-Related Blood Stream Infection (CRBSI) or Catheter-Line 
Associated Blood Stream Infection (CLABSI).  
Catheter-Related Blood Stream Infection (CRBSI) 
There are different definitions of CRBSI (2, 16, 17) used which all include a positive blood 
culture. The Swedish guidelines use the following definition (2): 1. The same microorganism 
found in the catheter blood or at the catheter tip and in a peripheral vein and 2. Systemic 
inflammation symptoms, without any other source of the infection. (Criteria for systemic 
inflammation symptoms are found under the paragraph Material and Methods - CRI definition) 
Catheter-Line Associated Blood Stream Infection (CLABSI).  
CLABSI is defined as a bloodstream infection in a central catheter that has been inserted longer 
than 48 hours, without any other source of infection (3). No confirming cultures are needed to 
classify the infection as CLABSI, but merely the lack of other focus for the infection than 
catheter-related. This definition could easily overvalue the incidence compared to CRBSI. In 
medical practice, CLABSI is more usable and CRBSI is more relevant at a scientific level.  
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Local infection 
A local infection includes redness with or without swelling and induration at the injection site 
and no signs of systemic inflammation or concomitant blood stream infection (2). This infection 
could lead to systemic inflammation and CRBSI, if not treated. 
Paired blood culture  
The blood cultures taken shall be paired : Blood cultures from each lumen (if having more than 
one) of the CVAD and the peripheral blood are drawn at the same time and are measured by 
time to positive blood culture (To verify CRBSI, blood culture from the CVAD should be 
positive within 2 hours before the blood culture from the peripheral vein)(2) or by quantity (the 
ratio of concentration of microorganisms from the CVAD and peripheral blood is more than 3-
5:1(18)). If one of these criteria is fulfilled, it is reasonable to assume that the infection 
originates from the CVAD (2). 
Pathogenesis 
The source of CRI is microorganisms migrating to the catheter (19): 
1) From the skin, along the outside 
of the catheter, to the tip,  
2) Through the catheter, by 
contamination of the catheter hub,  
3) From the blood to the catheter 
(hematogenous) 
4) From contaminated infusate. 
In long-term CVADs the most common source of infection is through the hub and in short-term 
CVADs from the skin (19). Coagulase-negative staphylococci or Staphylococcus aureus are 
the most common agents causing local infection (4). When the catheter is in place, a thin sheath 
of thrombin forms, in which microorganisms can adhere (19).  
Figure 3. Origin of the Catheter-Related Infection 
Picture adapted from (37). 
1. From the skin 
2. From contaminated 
catheter hub 
3. From the blood 
4. From 
contaminated 
infusate 
Fibrin sheath, 
biofilm 
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The bacteria can also adhere and aggregate on the catheter wall itself and form a biofilm. The 
adhesion is irreversible and the bacteria withstand antibiotic treatment. Hence the only way to 
cure an infection is to remove the CVAD. (20)  
Prevention 
In order to prevent CRI, one can focus on the ways CRI originates (See Figure 3):  
1. The skin: CRI can be prevented by good hygiene routines and skin cleansing.  
2. Contamination through the hub: CRI can be prevented by scrubbing the hub with 
alcohol (21). 
3. The blood: CRI can be prevented by awareness of general sickness symptoms and 
treating other infections in the body.  
4. The infusate: CRI can be prevented by using pre-filled syringes, when flushing the 
CVAD (22). 
The importance of prevention is emphasized by both scientists and public authorities. Provonost 
(23) examined the prevention of CRBSI by showing that hygiene routines, avoiding 
unnecessary CVADs and femoral insertion reduced the CRBSIs from 0.62 to 0.34/1000 
catheter-days in 18 months. Further, the Swedish Association of Local Authorities and Regions 
(24) has developed a bundle of measures for prevention of CRI, which stresses the points above 
and the importance of classifying the CRI adequately.  
CRI-incidence 
The incidence of CRI is preferably measured in CRI per 1000 catheter-days, which simplify the 
comparison between different CVADs, since they often are inserted for various time periods. 
The comparison of CRI still is difficult, since studies often use different definitions of CRI.  
The incidence of CLABSI in patients with PICC has shown to be 0.17-0.95 per 1000 catheter-
days (11, 13) and the CRI-incidence 0.067-0.76 per 1000 catheter-days in TIVAD patients  (25-
27).  
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In 2006, Maki et al. (28) showed in a systematic review including 200 prospective studies (not 
only in oncology patients), that patients with TIVAD has the lowest incidence for CRBSI, with 
0.1 CRBSI per 1000 catheter-days, while PICC had a CRBSI incidence of 1.0-2.1 per 1000 
catheter-days.  
Whether PICC is a safe long-term catheter choice has been debated (29, 30). Swedish Agency 
for Health Technology Assessment and Assessment of Social Services made an investigation 
of this in 2011, which was inconclusive due to too few high quality studies (1). The Swedish 
guidelines for central venous catheterization (2), from 2011, do not recommend PICC as a safe 
long term catheter choice. More recent studies indicate PICC to be a safe long term choice, 
regarding CRI (11, 13). There are few comparing studies of the CRI in patients with PICCs and 
TIVADs and some (29) focus only on complications and do not specifically look at CRI. 
Situation at Södra Älvsborg Hospital 
At Södra Älvsborg Hospital (SÄS), a secondary-level hospital in Western Sweden, which 
serves about 300 000 inhabitants, approximately 900 CVADs (CVC 67 %, PICC 20% and 
TIVAD 13 %) are inserted every year.  
Specially trained nurses at the Department of Oncology insert all PICCs and all the personnel 
are trained to take care of CVADs. The nurses keep an own register (apart from registering 
complications in the medical record) of all complications related to the PICCs. This is not done 
for TIVADs. 
TIVAD or PICC are both used as an intravenous access in oncology patients. The TIVAD might 
be difficult to get, because of low capacity at the operating theatre and the procedure must be 
scheduled a long time in advance compared to the PICC’s insertion at the Department of 
Oncology.  
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During 2014, the incidence of CRI increased in patients with TIVAD. An unpublished study 
showed a CRI-incidence of 34% in 2014. No calculation for CRI per 1000 catheter-days was 
made. Consequently, the routines were revised. 
According to SÄS guidelines (31), the use of CVAD shall be thoroughly documented, with 
emphasis to catheter complications. 
Medical relevance 
It is important for the clinician to have knowledge about which of PICC or TIVAD is the safest 
long term central catheter regarding CRI. 
Aim 
The aim of this study is to find whether PICC or TIVAD gives the lowest rate of CRI in patients 
with solid tumors. 
Research question: Does the incidence of CRI differ in oncology patients with PICC or TIVAD 
treatment during the years 2015-2016 at SÄS? 
Material and Methods 
Study group 
The study was a retrospective cohort study, conducted at Södra Älvsborg Hospital, in Västra 
Götaland, a region in south-west of Sweden. 560 medical records from oncological patients 
with either PICC or TIVAD, inserted at SÄS during January 2015 to December 2016, were 
analyzed. The medical records were reviewed for occurrence of CRI until CVAD removal or 
patient death. If none of the preceding occurred, the review lasted until the 3rd of August 2017. 
Inclusion criteria: Patients ≥18 years of age, with a PICC or TIVAD inserted at SÄS due to 
their oncological disease. Solely care events given at SÄS were reviewed. In cases where 
patients were transferred to another hospital at some point during their catheter treatment, care 
events were only reviewed until the transfer date and not until catheter removal.  
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Exclusion criteria: Age < 18 years, CVADs not inserted at SÄS and hematologic malignancy 
or diagnoses other than malignancy as reason for CVAD treatment.  
The patients were cared for at the Surgical or Medical Department. The PICCs were inserted 
by a special trained nurse in an examination room at the Department of Oncology and the 
TIVAD by an anesthesiologist in an operation theatre, with the continued care of the patient in 
respective department. 
The data was collected from the CVAD-file (definition below, under the paragraph 
Documentation) registered in the medical record software system “Melior” and through a search 
in Melior, using the truncated terms: “infekt” (eng. infect), “hemm”, “hemsj” (truncated terms 
referring to home nursing) and “rodnad” (eng. redness). 
CRI definition 
The medical records were examined regarding CRI in accordance with the Swedish Society of 
Anesthesiology and Intensive Care’s (SFAI) definition (2), with some modification to make it 
more applicable for a retrospective study. The criteria for the different infection types are seen 
below. 
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Local infection: Redness with or without pus, induration or swelling at the injection site. No signs of Systemic Inflammatory 
Response Syndrome (SIRS). Absence of concomitant blood stream infection. 
TIVAD infection: Local symptoms and a positive culture from the TIVAD injection chamber or the catheter tip. No signs of 
SIRS. Absence of concomitant blood stream infection. 
Catheter-tip infection (CTI): Positive culture from the catheter tip. Signs of SIRS. Absence of concomitant blood stream 
infection. No other source of infection.  
Catheter-related blood stream infection (CRBSI): The same microorganism is found in peripheral blood culture as in blood 
culture from PICC or TIVAD, or culture from the catheter tip. Signs of SIRS. No other source of infection.  
SIRS with unknown infection focus: Signs of SIRS where the infection focus is unknown, but catheter-related focus can’t be 
excluded. No positive blood culture. 
Systemic Inflammatory Response Syndrome (SIRS): ≥ 2 of the following clinical findings: temperature > 38 or <36º C, heart 
rate > 90 beats/minute, respiratory rate > 20 breaths/minute, B-leukocytes <4·109 /liter or >12·109/liter.  
Fact box 1. Definitions of Catheter-Related Infection.  
SIRS = Systemic Inflammatory Response Syndrome, TIVAD = Totally Implantable Venous Access Device, 
PICC = Peripherally Inserted Central Catheter 
 
 
It is only possible to get one CRI per CVAD. If fulfilling a diagnosis with more severe criteria, 
the former is excluded. For example, if it is redness and swelling around the injection site 
(=local infection) and the catheter tip of the TIVAD has a positive culture (=TIVAD infection), 
it is classified as a TIVAD infection.  
The medical records did not always include paired blood cultures and therefore the CRI-
diagnose did included this in this study. 
The CRI have also been categorized as either Confirmed or Uncertain: 
Confirmed CRI: The physician diagnosed and treated the event as a CRI or when above criteria (See Fact box 1) were fulfilled 
and a positive culture (from the blood or the wound) were obtained.  
Uncertain CRI: The medical records or diagnostics were faulty, making it difficult or impossible to classify the infections as 
catheter-related, but still not being able to exclude the possibility. 
Fact box 2. Main groups of the Catheter-Related Infections  
CRI = Catheter-Related Infection 
Infections that were complicated to categorize were co-assessed with the study supervisor Maria 
Werner, a consultant in the infectious diseases and infection control. For example, one patient 
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with PICC had fever spikes without infection focus nor SIRS-symptoms at several times during 
a couple of months. After treatment, the PICC was removed and a culture was taken from the 
catheter tip, because of the previous fever spikes. At the time, the patient had no infection 
symptoms and the culture showed meagre of Coagulase negative staphylococci. This was 
judged to be a contamination, caused when the catheter was removed. Thus, this episode is not 
part of the CRI-analysis, since it is not an infection nor colonization, but shows the complexity 
of classifying infections with only the medical record as the source of information. 
The date of infection was set to the first day when SIRS criteria or local infection criteria were 
met. In case the patient was treated for infection and discharged and then returned with infection 
symptoms again (no time limit was set), it was considered to be the same infection that had not 
properly healed. The date of infection was still set to the first day of the first episode and the 
last episode was not reported as a new infection. 
Variables  
The examination protocol also included age, sex, diagnosis, catheter type, insertion date, reason 
for insertion, removal date, reason for removal, date of infection start, health care facility, 
chemotherapy, body mass index (BMI) and CVAD documentation compliance. 
The diagnoses were categorized into cancer type groups: gastrointestinal cancer, gynecologic 
cancer, lung cancer, breast cancer and other malignancies (included peritoneal cancer, thyroid 
cancer, brain tumour, skin cancer, hypopharyngeal cancer, laryngeal cancer, liver cancer, 
neuroendocrine tumor (NET), kidney cancer, prostate cancer, testicular cancer, bladder cancer, 
oral cancer, sarcoma and cancer of unknown primary). In cases of disseminated cancer, the 
primary tumour determined the categorization of cancer type.  
If the removal date was not documented or unclear and there was an uncertainty whether the 
CVAD was still in use, the review ended at the last seen notation of the CVAD. The same 
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procedure was used when the patient was transferred to another hospital, health care facility or 
went home with home health nursing.  
BMI was registered in the protocol if measured one month prior to one month after insertion of 
the CVAD.  
CVAD-Documentation 
A part of the study was to determine if the documentation in the digital medical records related 
to CVAD procedures had been made according to SÄS’ guidelines (31), with the aim to validate 
the study data. 
Every CVAD was obliged to have an own file, sorted in the correct place in the medical record. 
Furthermore, the documentation of the CVAD needed to include: indication, removal date, 
reason for removal, possible complications and have a separate connecting file for the treatment 
of the CVAD.  
If the medical record included all the above conditions, it was classified as “adequate 
compliance” regarding present guidelines. If not, it was classified as “inadequate compliance”. 
Concerning possible complications, the only complication that was considered during the 
review of the material was CRI. In the material, undocumented (as a complication in the 
CVAD-file) catheter-related thrombosis were found as a coincidence. Since thrombosis was not 
subject of this study more cases of thrombosis could have occurred without being documented 
in the CVAD-file.  
Statistical methods 
470 CVADs divided into two groups of 235 CVADs each, were needed to achieve 80 % power 
with a significance level of 95 %. 
All descriptive variables had their mean, median, range and percentage calculated when 
appropriate. 
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The number of catheter days was calculated as the difference between the removal date and the 
insertion date. To get CRI per 1000 catheter-days, the number of CRI were divided with the 
total sum of catheter-days in respective CVAD and multiplied by 1000. The total sum of 
catheter-days was calculated by summarizing the catheter-days until infection occurred and 
adding the rest of the non-infected CVADs’ individual catheter-days.  
Kaplan-Meier survival analysis for PICC and TIVAD were made, both for the Total CRI-group 
(Uncertain and Confirmed CRI) and the Confirmed CRI-group.  
A Cox regression adjusted for age, sex, cancer type group and BMI was made. Statistical 
significance was set to p≤0,05. 
All statistical calculations were performed with the computer program IBM SPSS Statistics 25. 
Ethics 
The study is a retrospective cohort study and therefore has no physical implications for the 
patients. The ethical consideration involves preservation of the patient’s integrity. The patient 
secrecy is preserved by encrypting any digital documents containing personal data and no 
personal data is included in the report. Every patient is given a serial number, which is linked 
to the personal identity number using a code key, stored in paper form in a locked archive at 
the Department of Infectious Diseases, SÄS, until the year 2027. 
The study has been approved by the Head Physician at SÄS, Jerker Isacsson (See Appendix 1) 
and by the Consultants Ulf-Henrik Mellqvist at the Department of Oncology at SÄS and Nina 
Sjövall Widfelt at the Department of Anesthesiology at SÄS.  
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Results 
Baseline data 
556 CVAD episodes (328 PICC and 228 TIVAD) took part in the study. After exclusion, 356 
CVAD episodes (165 TIVAD and 191 PICC) in 320 patients (242 women and 78 men) were 
analyzed (See Figure 4).  
 
34 of the patients had two or three central catheters, of which 15 patients had both PICC and 
TIVAD. Only one central catheter was inserted at a time. Baseline characteristics of the CVAD 
episodes are shown in Table 2.  
The total amount of catheter-days in the TIVAD group was 48 017 and 15 476 in the PICC 
group respectively (See Table 3). Reasons for removal of the CVADs are shown in Table 4.  
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Catheter-Related Infection (CRI) 
There was a total of 46 episodes of CRI in the TIVAD group (27.9% of all episodes; 24 
Confirmed and 22 Uncertain) and 26 episodes of CRI in the PICC group (13.6% of all episodes; 
2 Confirmed and 24 Uncertain). Further subcategories of the Confirmed CRI are seen in Table 
5.  
The number of catheter-days until CRI are shown in Table 3.  
The total CRI rate in TIVAD were 1.04 per 1000 catheter-days and 0.5 per 1000 catheter-days 
in the Confirmed CRI-group. The same numbers for PICC were 1.77 in the Total CRI-group 
and 0.13 in the Confirmed CRI-group (See Table 5). 
The Kaplan Meier survival function showed no significant difference in CRI-incidence between 
PICC and TIVAD.  
There were two models of multivariate analysis of the CRI: Model 1, the Total CRI-group 
(Table 6) and Model 2, the Confirmed CRI-group (Table 7). Both models were adjusted for 
CVAD, sex, age, diagnose group and BMI. In Model 1, the Hazard Ratio (HR) for PICC was 
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1.03 (95 % Confidence Interval (CI): 0.44-2.16, p=0.95), thus a 3% higher risk of getting a CRI 
if having PICC, but the difference was not significant. It was a significantly lower risk to get a 
CRI for a woman (HR=0.44, CI: 0.21-0.92, p= 0.03) and a significantly higher risk to get a CRI 
for lung cancer patients (HR=7.34, CI: 1.38-38.96, p=0.02) (See Figure 5 and Table 6). 
Model 2 showed a 91% lower risk of getting a Confirmed CRI if having a PICC (HR=0.09, CI: 
0.01-0.87, p=0.04). None of the other variables were statistically significant (See Figure 6 and 
Table 7). 
Figure 6. Kaplan-Meier survival function for the 
Confirmed CRI-group, adjusted for CVAD, sex, age, 
diagnose group and BMI. 
CRI = Catheter-Related Infection, CVAD = Central Venous 
Access Device, PICC = Peripherally Inserted Central Catheter, 
TIVAD = Totally Implantable Venous Access Device 
Figure 5. Kaplan-Meier survival function for the Total CRI-
group, adjusted for CVAD, sex, age, diagnose group and BMI. 
CRI = Catheter-Related Infection, CVAD = Central Venous 
Access Device, PICC = Peripherally Inserted Central Catheter, 
TIVAD = Totally Implantable Venous Access Device 
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Compliance to guidelines for 
documentation  
Criteria for adequate documentation of 
CVAD were met for 103 (62.4%) TIVADs 
and 147 (77.0%) PICCs. All Confirmed 
CRIs in PICC were documented under 
Complications in the CVAD-file and 91.7% 
(22 of 24) of the Confirmed CRIs in TIVAD 
(See Table 8). 
Discussion 
The study shows that there is not a 
significant difference in the Total CRI-
incidence between PICC and TIVAD patients. This differ from previous conclusions (2, 3) 
which indicates that TIVAD is a safer choice than PICC, considering CRI. 
Although, the analysis of the Confirmed CRI showed a significantly lower risk of CRI in PICC 
compared to TIVAD. The result is uncertain to rely on since the difference between the 
Confirmed CRI-group and the Total CRI-group is based on the Uncertain CRI-episodes. These 
episodes were infections that possibly, but not guaranteed, could be caused by the CVAD. 
Consisting either of true CRI-episodes with inferior diagnostics or other infections with inferior 
diagnostics. It is also important to note that some studies (11, 13) define CRI as CLABSI 
(defined as a positive blood culture and lack of other infection focus than the CVAD). Meaning 
that these CLABSIs might be misclassified. Considering the Uncertain episodes of CRI 
included in the Total CRI-group in this study, they do not have a confirming blood or wound 
culture nor a physician’s confirming diagnosis, but merely a possibility to be catheter-related. 
They might be CRI, but could also be a neutropenic fever or another infection that the 
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diagnostics failed to find. Therefore, based on this study’s result of the Confirmed CRI, it is 
possible that PICC might be an even better alternative than TIVAD, regarding CRI. 
Furthermore, there was a significant difference between the Confirmed CRI-groups, that larger 
study groups as implied by the power analysis, were not needed. While in the Total CRI-group 
(including Uncertain CRI) no significant difference was found, which might depend on that the 
study group size did not fulfill the sizes of the power computed. 
The study result is based on the follow-up time of the patients. Since 59 of the patients in the 
TIVAD-group (See Table 4) still had their TIVAD inserted at study completion and none in the 
PICC-group, the result is uncertain. If the remaining 59 patients with TIVAD had it inserted for 
100 days more, it equals with 5900 more catheter-days, which could alter the result, but as we 
consider the risk of getting CRI to be the same every day it would not affect the result. To obtain 
an even more reliable result, only CVADs with follow-up until removal or the patient deceased 
should have been included in the study. 
In addition, in 6.1% (n=10) of the episodes in TIVAD and 4.7% (n=9) in PICC the removal 
date was unknown (See Table 4) and the records were reviewed until the last notation of the 
CVAD, which could have given these CVADs a shorter catheter-time. Although, it was so few 
episodes that it probably does not have an implication on the result. 
During the study, it emerged that TIVAD usually is chosen for patients in palliative care and 
PICC is usually chosen for patients with curative-intended treatment. A group with palliative 
care and one with curative-intended treatment cannot be considered equivalent groups, since 
palliative care probably is linked to a higher tendency to get infections. 
Further, CRI can be categorized as early onset (the first 30 days (32)) or late onset, something 
that was not considered in this study. Early onset infection relates to the insertion and late onset 
relates to the treatment of the CVAD. In Table 3, the CRIs tend to occur late onset, in median 
 
 
24 
92 days in the Total CRI-group for TIVAD and 20 days for PICC. The catheter-time is longer 
in TIVAD in all groups, except in the Confirmed CRI-group, where the mean catheter-time is 
longer in PICC (120 days compared to 109 days), although, the PICC group consisted of only 
two episodes.  
In the PICC and TIVAD groups there were 34 patients that appeared more than once, as they 
had been treated with more than one CVAD. These patients could get CRI in both of their 
CVADs, but would not be considered the same infection, since (20) the biofilm with attached 
bacteria are removed along with the catheter (20), hence, the CRI is treated (19). In addition, in 
occasions when PICC preceded TIVAD or vice versa, a possible CRI was considered unrelated 
since the CVADs are inserted at different places.  
Study population 
Sex and age  
The groups in Table 2, appear similar, both populations have a predominance of women, more 
distinct in the PICC-group (81% in PICC and 69% in TIVAD). This may be caused by the 
predominance of breast cancer in the PICC-group. Also, the lack of men could be caused by 
the fact that prostate cancer, the most common cancer in men, is not often treated with 
chemotherapy and consequently no CVAD is needed for the. Noticeable, is a greater range in 
age (23-84 years) in PICC patients compared to TIVAD patients (40-88 years), but the mean 
and median age were quite similar (PICC 59.7 and 62 years, TIVAD 63.7 and 65 years) 
indicating that there probably not was a greater difference in age. 
BMI 
We considered BMI under 18.5 a pseudo marker for a patient who might be in palliative care. 
Presumably, the incidence of CRI should have been increased in this group. The TIVAD group 
had more underweight patients and the PICC group had more obese patients, when looking at 
the range (Table 2). The multivariate analysis did not show a significant result for the group of 
patients with BMI under 18,5. Although, this group only consisted of 10 patients. There was 
 
 
25 
also a lot of BMI-data missing (almost 50% in the TIVAD-group and 30% in PICC-group), 
which means it is not possible to draw a conclusion from BMI. Low BMI might have had a 
bigger impact on the CRI-incidence if a larger sized group with complete data had been studied. 
One study (33) found obese patients to have an increased complication rate. No such results 
were found in this study.  
Malignancies and chemotherapy 
The malignancies in the different CVAD groups differed in numbers. This could indicate that 
the groups were not as similar as thought when starting the study. Each cancer type accompanies 
with its own burden of disease, neutropenia and chemotherapy. The chemotherapy itself might 
have had an impact on the result. Possibly, some type of chemotherapy facilitates CRI more 
than other chemotherapy, as Bertoglio et al. (13) found in their study. 
Health care facility 
Our hypothesis that home health nursing leads to more CRI (when the personnel might not have 
the same experience and training in taking care of CVADs) cannot be concluded, since there 
was a large decline in data, with almost 30% inconclusive data in the TIVAD-group. In the 
PICC group, only 7.9 % (n=15) of the patients had home health nursing, which might be a 
reason for the lower CRI-incidence in this group (See Table 2).  
CRI 
The CRIs were analyzed in two different groups: Confirmed CRI and Total CRI (including 
episodes of Uncertain CRI).  
The CRI-incidence in the Confirmed CRI-group for TIVAD was 0.5 per 1000 catheter-days 
and for PICC 0.13 per 1000 catheter-days, which is comparable with earlier studies (11, 25-27).   
Considering how the CRI originates, the tending of the CVAD is of utmost importance, since 
the most common contamination is through the hub (19). Depending on the skill of whom takes 
care of the treatment of the CVAD (personnel, patient or relative), contamination risk might 
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differ. Other factors, like type of treatment administrated through the CVAD (32), skin 
problems or amount of subcutaneous fat (when implanting a TIVAD) could differentiate the 
CRI-risk. 
It only occurred two episodes of Confirmed CRI in the PICC-group. This might be because the 
PICC-group mainly consisted of breast cancer patients, who often do not have a great co-
morbidity. Furthermore, breast cancer patients are treated at the Department of Oncology, 
where the personnel have special training in taking care of PICCs. The fact that most of the 
patients (89.5%, n=171) were inpatients (meaning that the care of the CVAD was given at the 
hospital) also indicates better treatment of the PICC.  
Looking at the TIVAD group, it occurred 24 Confirmed episodes of CRI. 26 patients (15.8%) 
had home health nursing, which might be associated with higher CRI-risk. There was an 
obscurity in almost 30% of the data, if all of these had home health nursing together it would 
constitute almost half of the TIVAD-episodes. In the PICC-group, only 7.9% had home health 
nursing and 2.6% were unclear data. 
To further decrease the incidence of CRI in the TIVADs, an intervention could be made, with 
focus on education of both personnel and patients in hygiene routines and information about 
current CVAD guidelines. A TIVAD-team, a smaller group handling the care of the TIVADs, 
might be of great value. 
Additional factors that previous work have found to be associated with a higher CRI-incidence 
is the CVAD material (19) and age less than 40 years (34). The CVAD-material were not 
considered in this study and might have had implications on the result, while the age was not 
related to a higher CRI-risk. 
The multivariate analysis in the Total CRI-group also showed that women have a lower risk 
and lung cancer patients has a higher risk of getting CRI. One can speculate why women have 
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a lower risk of CRI: perhaps they seek medical care more often than men, they have better self-
care or the hormonal difference is crucial. The subgroup of lung cancer patients has a high risk 
of CRI, although the result should be interpreted with care considering the large confidence 
interval (CI=1.38-38.96) (See Table 6). Further studies need to be made in order to find the 
reason for these indications. 
Clinical documentation 
The more adequacies in documentation for PICC (See Table 8) could be due to that all PICCs 
are inserted and many are managed by nurses at the Department of Oncology, a small and well-
organized group. While patients with TIVAD has different responsible personnel, depending 
on which diagnosis the patient has got. The documentation might be missed more easily in the 
TIVAD group. 
The fact that thrombosis occurred without being documented as a complication in the CVAD-
file indicates that there may be more complications that fail to be documented.  
Study limitations 
First, there was a validation bias, since only one person reviewed the records. Consequently, 
CRIs could have been missed or misjudged. At the end of the study, knowledge and proficiency 
were acquired, thus the later CVAD episodes got a better assessment. Complex cases were co-
assessed, making error less likely.  
Second, being a retrospective medical record review, all information obtained originated from 
written medical records. The quality of the records differed and the possibility to classify 
infections were sometimes not optimum. In addition, the study was based on the diagnosis of 
CRI set up for the study and a part of the criteria was SIRS-symptoms. In Sweden, it is medical 
practice to diagnose infections with C-Reactive Protein (CRP), which is not included in the 
SIRS criteria. Making the CRI diagnose sometimes impossible to verify, when there only is 
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CRP and fever in the medical records. Also, there is a possibility that the clinicians use different 
definitions of CRI. 
To find whether PICC or TIVAD is the safest regarding CRI, a Randomized Controlled Trial 
(RCT) is of interest. Only a few such studies have been done. One (29) was made in 2013, 
comparing the complications in PICC and TIVAD. TIVAD had less complications than PICC, 
but the study did not present specific statistics for CRI. A new RCT, focused on CRI, could 
possibly sort out whether there is a real difference in CRI-incidence between PICC and TIVAD. 
Third, when reviewing a medical record by using truncated search terms, it relies on the 
personnel using the same terms to describe infection. If not, infections can be missed. The word 
infection might not have been used, but instead fever, tachypnea or antibiotics. To avoid this, 
the full length of the medical records needs to be read, which for this study was not manageable. 
Fourth, there might be a selection bias, since it is possible that most of the patients with TIVAD 
are in palliative care. This is not consolidated, but if it is true the study groups are not equivalent. 
Fifth, if the patients in the home health nursing are managing their CVADs themselves there 
might be an increase in the CRI-risk. Comparing inpatients with patients with self-care of the 
CVAD are not equivalent groups either. 
Conclusion 
The study did not find a significant difference in CRI-incidence in the Total CRI-group, 
between PICC and TIVAD in patients with solid tumors, meaning that both catheters make a 
safe long-term CVAD choice. Possibly, PICC is an even safer alternative, when considering 
that in the Confirmed CRI-group a significantly lower risk for CRI in patients with PICC 
compared to TIVAD was shown. The incidence of Confirmed-CRI was low (0.05 for TIVAD 
and 0.13 for PICC) and equivalent with earlier studies. 
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The uncertainties of how many of the patients were in palliative care might have had 
implications on the result. Apart from this, the findings are interesting in a view of comparing 
two different CVADs, since many of the studies done are single CVAD studies.  
The Uncertain CRIs (in the Total CRI-group) were characterized by inadequate diagnostics and 
documentation. Hence, the quality needs to improve to prevent these shortcomings. 
Further prospective studies are of interest to compare the CRI-incidence in different CVADs 
the oncological population.  
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Populärvetenskaplig sammanfattning 
Vilken kärlkateter ger lägst infektionsrisk hos cancerpatienter? 
Kateterrelaterad infektion orsakar sjuklighet och kan ibland vara livshotande hos patienter med 
central kärlkateter. En central kärlkateter är en kateter som sätts i ett blodkärl nära hjärtat, vilket 
möjliggör kontinuerlig tillgång till blodbanan. Genom den kan man bland annat ge kärlretande 
läkemedel, stora volymer vätska och blod.  
Antalet kateterrelaterade infektioner varierar mellan olika centrala kärlkatetrar, vilket är viktigt 
att veta inom vården så rätt kateter väljs vid rätt tillfälle. I cancervården används bland annat 
subkutan venport och perifert insatt central kateter (PICC). PICC kallas perifer för att den läggs 
via ett blodkärl i armen (istället för ett blodkärl nära hjärtat direkt) och löper sedan genom 
blodbanan och slutar precis i anslutning till hjärtat. Subkutan venport består av en dosa som 
opereras in under huden (subkutan = under huden) strax under nyckelbenet. Ifrån dosan går en 
kateter in i ett centralt blodkärl och slutar precis i anslutning till hjärtat. En nål sticks sedan i 
dosan då man vill få åtkomst till blodbanan. 
Patienter som har en central kärlkateter kan drabbas av infektioner och det är även en vanlig 
orsak till att katetern tas ut tidigare än planerat. Att minska de kateterrelaterade infektionerna 
är viktigt. Ett sätt att göra det är att veta vilken kateter som ger lägst antal infektioner hos olika 
patientkategorier. Exempelvis används subkutan venport till patienter som behöver en central 
kärlkateter under lång tid, eftersom den anses vara förknippad med färre infektioner. 
Syftet med studien var att ta reda på om det är någon skillnad i kateterrelaterad 
infektionsförekomst hos patienter med cancer (all cancer utom blodcancer), som har antingen 
en PICC eller en subkutan venport. 
I studien analyserades 356 journaler tillhörande cancerpatienter med PICC eller subkutan 
venport.  
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Studien fann inte någon skillnad för cancerpatienter att få kateterrelaterad infektion om man 
hade subkutan venport eller PICC. Möjligen skulle PICC vara ett bättre alternativ, men 
infektionsdiagnostiken var för undermålig för att vara säker. Det var även osäkert hur många 
av patienterna som vårdades i livets slutskede, vilket kan inverka på resultatet. För att ytterligare 
utreda kateterrelaterade infektionsförekomsten och säkerställa resultatet krävs förbättrade 
studier. 
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